【學位/學曆】    博士(PhD)    

【學術簡曆】
  2009年和2012年分别獲太阳集团app首页本科和碩士學位。2016年獲香港中文大學博士學位(全額獎學金資助),同年進入太阳集团app首页腫瘤防治中心工作至今。2021年獲聘副研究員,主要從事統計學方法及其醫學應用、臨床流行病學、臨床研究方法學等方面的教學、教改及科研工作。目前,主持國家自然科學基金、廣東省自然科學基金、美國中華醫學基金會(CMB)等多項科研課題,第一/通訊作者在BMC medicine等期刊發表研究論著30餘篇。

【學術/社會兼職】
1.  中國抗癌協會期刊出版專業委員會,委員
2.  廣東省醫療器械行業協會臨床試驗規範化委員會,副主任委員
3.  廣東省藥品注冊核查專家
4.  中國臨床腫瘤學會青年委員會,統計小組成員
5.  廣東省藥學會藥物臨床試驗專業委員會,統計學專業組秘書
6.  Frontiers in Nutrition、Journal of affective disorder、中國醫院統計、腫瘤預防與治療、《clinical trial》中文版等期刊編委會委員或審稿人

【主要承擔科研項目】
1. 美國中華醫學基金會(CMB),2023-2025,主持。
2. 太阳集团app首页青年教師團隊項目子課題,2022-2023,主持。
3. 廣東省自然科學基金面上項目,2021-2023,主持。
4. 國家自然科學基金青年項目,2019-2021,主持。
5. 廣東省自然科學基金博士啟動項目,2018-2020,主持。
6. 廣東省醫學科學技術基金,2018-2020,主持。

【主要承擔教改項目】
1.  廣東省研究生教育創新計劃項目,2023/01-2023/12,主持。
2.  太阳集团app首页本科教學質量工程類建設項目,2022-2023,主持。
3.  太阳集团app首页本科教學質量工程類重點教材建設項目,2019-2020,主持。
4.  太阳集团app首页本科教學質量工程類建設項目,2018-2019,主持。

【代表性學術成果】(*通訊作者)
1.    Li JB*; Zhuo-Chen Lin; Martin CS Wong; Harry HX Wang; Mengmeng Li; Su Li. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society. BMC Med. 2022; 20(1): 320. 
2.    Wei W, Ban X, Yang F, Li JB (co-first author), Cheng X, Zhang R, Huang X, Huang Y, Li Q, Qiu Y, Zheng M, Zhu X, Li J. Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer. 2022; 10(5): e004338.
3.    Li JB, Ke KJ, Zhang WL, Wang LY, Wu YP, Weng F, Tian H, Qiu ZY, Li Y, Lin SY, Ye MX, Ou QJ, Gong CH, Lu ZH, Pan ZZ, Wan DS, Peng JH*, Fang YJ*. Factors associated with colonoscopy adherence among individuals who were positive in the preliminary screening for colorectal neoplasms. Cancer Med. 2022 Apr 20. doi: 10.1002/cam4.4730.
4.    Li JB, Lau JTF, Feng LF, Zhang X, Li JH, Mai JC, Chen YX, Mo PKH*. Associations of intensity and emotional connection related to online social networking use on the risk of incident depression among Chinese adolescents: A prospective cohort study. J Affect Disord. 2022 Apr 12: S0165-0327(22)00366-4.
5.    Li JB, Qiu ZY, Deng YX, Li Y, Lin ZC, Wu YP, Weng F, Tian H, Ou QJ, Gong CH, Pan ZZ, Wan DS, Peng JH*, Fang YJ*. Factors associated with positive predictive value of preliminary screening in a two-step screening strategy for colorectal neoplasms in China. Discover Oncology, 2022, 13(1): 1-11.
6.    Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M*. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2021; JCO2101963.
7.    Li JB, Feng LF, Wu AMS, Mai JC, Chen YX, Mo PKH, Lau JTF. Roles of Psychosocial Factors on the Association Between Online Social Networking Use Intensity and Depressive Symptoms Among Adolescents: Prospective Cohort Study. J Med Internet Res. 2021 Sep 21; 23 (9): e21316. 
8.    Li JB, Wu AMS, Feng LF, Deng Y, Li JH, Chen YX, Mai JC, Mo PKH, Lau TJF. Classification of online social networking addiction: a latent profile analysis from a large-scale survey among Chinese adolescents. J Behav Addict, 2020;10.1556/2006.2020.00047.
9.    Li JB, Qiu ZY, Liu Z, Zhou Q, Feng LF, Li JD, Zhang X.  Gender differences in factors associated with clinically meaningful weight loss among overweight or obese adults: a population-based cohort study. Obesity facts, 2020. doi: 10.1159/000512294.
10.    Li JB, Guo SS, Tang LQ, Guo L, Mo HY, Chen QY, Mai HQ. Longitudinal Trend of Health-Related Quality of Life during Concurrent Chemoradiotherapy and Survival in Patients with Stage II–IVb Nasopharyngeal Carcinoma. Front Oncol, 2020 Oct 8;10:579292. doi: 10.3389/fonc.2020.579292.
11.    Li JB, Wu YW, Gu DT, Li HJ*, Zhang X*. Prevalence and temporal trends of presarcopenia metrics and related body composition measurements from the 1999 to 2006 NHANES. BMJ Open, 2020;10: e034495.
12.    Wang X, Li JB (共同第1作者), Shi W, Huang ZZ, Xia W, Huang JJ, Su YH, Wang SS, Shi YX, Bi XW, Yuan ZY. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. Oncologist. 2020;10.1634/theoncologist.2020-0364.
13.    Gu DT, Li JB (共同第1作者), Little JL, Li HJ, Zhang X. Associations between serum sex hormone concentrations and telomere length among U.S. adults, 1999-2002. J Nutr Health Aging, 2020; 24 (1): 48-54.
14.    Mo PK, Li JB (共同第1作者), Jiang H, Lau JTF. Problematic Internet Use and Smoking among Chinese Junior Secondary Students: The Mediating Role of Depressive Symptomatology and Family Support. Int J Environ Res Public Health. 2019 Dec 11;16(24):5053
15.    Li JB, Luo S, Wong MCS, Li C, Feng LF, Peng JH, Li JH, Zhang X. Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults. BMC Cancer, 2019; 19 (1): 1082.
16.    Wang ZQ, Mei Q, Li JB (共同第1作者), You R, Liu YP, Sun R, Hu GY, Chen MY, Hua YJ. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer, 2019, 19 (1): 1122.
17.    Li JB, Liu Q, Yang H, Fu J. Reply to Z. McCaw and L-J. Wei. J Clin Oncol. 2019 Apr 20;37(12):1034. doi: 10.1200/JCO.18.01829. 
18.    Li JB, Mo PKH, Lau JTF, Su XF, Zhang X, Wu AMS, Mai JC, Chen YX. Online social networking addiction and depression: The results from a large-scale prospective cohort study in Chinese adolescents. J Behav Addict. 2018 Sep 1;7(3):686-696.
19.    邱智宇,李濟賓(通訊作者). 結直腸癌篩查方法研究進展. 腫瘤預防與治療,2019,32 (11): 1024-1030.

【教材與專著】
[1].    李濟賓、張晉昕、洪明晃主編,《臨床研究方法學》,北京:科學出版社,2020。 
[2].    徐瑞華、陳國強主編,李濟賓為參編人員,《腫瘤學》,北京:人民衛生出版社,2020。 
[3].    徐瑞華、萬德森主編,李濟賓為編委,《臨床腫瘤學》,北京:科學出版社,2020。 
[4].    仇麗霞主編,李濟賓為編者,《醫學統計學(3版)》,北京:中國協和醫科大學出版社,2018。 
[5].    宇傳華、許傳志主編,李濟賓為編委,《調查研究方法與分析》,北京:中國統計出版社,2016。 

【獲獎情況】
[1].    2022年,太阳集团app首页校級一流課程(負責人)
[2].    2021年,太阳集团app首页校級教學成果獎一等獎(第一完成人)
[3].    2020年,太阳集团app首页腫瘤防治中心青年教師授課競賽三等獎
[4].    2010年,廣東省南粵優秀研究生

【招生方向】
流行病與衛生統計學碩士
公共衛生碩士(MPH)